Pharma's Harsh Week: Breast Cancer Pill Flops, Novo Nordisk Rebrands in Panic

AstraZeneca's newly approved breast cancer pill Etcamah just failed its biggest test. The drug, a selective estrogen receptor degrader (SERD) meant to replace old injectable therapies, did not significantly delay disease progression when used as a first-line treatment in advanced breast cancer. The setback means Etcamah's path to becoming a blockbuster is now much narrower, with the company once hoping for $5 billion in annual sales.

Zoom Out

AstraZeneca isn't alone in its...